The mid-cycle review should be an important confirmation that everything is on track. And that confirmation, while not too important in itself, does send strong signals to the market and to big pharma (who will almost certainly be watching carefully). Will it have an impact on SP? That is entirely for the market to decide, but you may see a pharma company start to build a stake, and then it starts to get really interesting.
The mid-cycle review should be an important confirmation that...
-
- There are more pages in this discussion • 8,244 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
37.0¢ |
Change
-0.010(2.63%) |
Mkt cap ! $669.7M | |||
| Open | High | Low | Value | Volume |
| 38.0¢ | 38.5¢ | 36.5¢ | $2.548M | 6.766M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 96148 | 36.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 37.0¢ | 782479 | 9 |
View Market Depth
| Last trade - 16.10pm 16/08/2024 (20 minute delay) ? |
| BOT (ASX) Chart |